 Rivaroxaban
"Rivaroxaban" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.
| Descriptor ID |
D000069552
|
| MeSH Number(s) |
D02.886.778.727 D03.383.533.640.713 D03.383.903.727
|
| Concept/Terms |
Rivaroxaban- Rivaroxaban
- 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide
|
Below are MeSH descriptors whose meaning is more general than "Rivaroxaban".
Below are MeSH descriptors whose meaning is more specific than "Rivaroxaban".
This graph shows the total number of publications written about "Rivaroxaban" by people in this website by year, and whether "Rivaroxaban" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 3 | 3 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 8 | 8 | | 2014 | 0 | 11 | 11 | | 2015 | 4 | 1 | 5 | | 2016 | 6 | 6 | 12 | | 2017 | 8 | 2 | 10 | | 2018 | 8 | 4 | 12 | | 2019 | 14 | 3 | 17 | | 2020 | 16 | 4 | 20 | | 2021 | 13 | 7 | 20 | | 2022 | 1 | 6 | 7 | | 2023 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Rivaroxaban" by people in Profiles.
-
Sandhu A, Kaltenbach LA, Chiswell K, Shimoga V, Ashur C, Pribish A, Fonarow GC, Piccini JP, Ho PM, Varosy PD, Hess PL. Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2023 12; 16(12):e010062.
-
Rymer J, Anand SS, Sebastian Debus E, Haskell LP, Hess CN, Jones WS, Muehlhofer E, Berkowitz SD, Bauersachs RM, Bonaca MP, Patel MR. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation. 2023 12 12; 148(24):1919-1928.
-
Piazza G, Spyropoulos AC, Hsia J, Goldin M, Towner WJ, Go AS, Bull TM, Weng S, Lipardi C, Barnathan ES, Bonaca MP. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial. Circulation. 2023 06 20; 147(25):1891-1901.
-
Zghaib T, Allison JD, Barrett C, Arkles J, D'Souza B, Luebbert J, Garcia F, Heist EK, Tzou W, Callans D, Marchlinski FE, Frankel DS. Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2023 03; 34(3):593-597.
-
Govsyeyev N, Nehler M, Conte MS, Debus S, Chung J, Dorigo W, Gudz I, Krievins D, Mills J, Moll F, Norgren L, Piffaretti G, Powell R, Szalay D, Sillesen H, Wohlauer M, Szarek M, Bauersachs RM, Anand SS, Patel MR, Capell WH, Jaeger N, Hess CN, Muehlhofer E, Haskell LP, Berkowitz SD, Bonaca MP. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. J Vasc Surg. 2023 04; 77(4):1107-1118.e2.
-
Vanassche T, Verhamme P, Anand SS, Shestakovska O, Leong DP, Fox KAA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Muehlhofer E, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2022 08 11; 8(5):462-473.
-
Hess CN, Baumgartner I, Anand SS, Nehler MR, Patel MR, Debus ES, Szarek M, Capell W, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP, Hsia J. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Heart Assoc. 2022 06 21; 11(12):e024655.
-
Novak AR, Shakowski C, Trujillo TC, Wright GC, Mueller SW, Kiser TH. Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism. J Thromb Thrombolysis. 2022 Aug; 54(2):276-286.
-
Hess CN, Szarek M, Anand SS, Bauersachs RM, Patel MR, Debus ES, Nehler MR, Capell WH, Beckman JA, Piazza G, Henkin S, Bura-Rivi?re A, Lawall H, Roztocil K, Hsia J, Muehlhofer E, Berkowitz SD, Haskell LP, Bonaca MP. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Netw Open. 2022 06 01; 5(6):e2215580.
-
Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, Debus S, Fox KAA, Liang Y, Muehlhofer E, Nehler M, Haskell LP, Patel M, Szarek M, Yusuf S, Eikelboom J, Bonaca MP. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. Eur J Prev Cardiol. 2022 05 05; 29(5):e181-e189.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|